ATTBF — Abattis Bioceuticals Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$1.93m
- CA$0.36m
Annual income statement for Abattis Bioceuticals, fiscal year end - September 30th, CAD millions except per share, conversion factor applied.
2015 September 30th | 2016 September 30th | 2017 September 30th | 2018 September 30th | 2019 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.092 | 0 | 0 | 0.008 | 0.357 |
| Cost of Revenue | |||||
| Gross Profit | 0.063 | 0 | — | 0.006 | 0.241 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 5.8 | 2.32 | 7.32 | 70.2 | 4.08 |
| Operating Profit | -5.71 | -2.32 | -7.32 | -70.1 | -3.72 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -5.99 | -2.41 | -7.93 | -77.7 | -3.06 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -5.57 | -2.41 | -7.93 | -77.7 | -3.06 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -4.47 | -2.34 | -7.63 | -78 | -3.04 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -4.47 | -2.34 | -7.63 | -78 | -3.04 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.037 | -0.025 | -0.045 | -0.073 | -0.007 |
| Dividends per Share |